title: Beginning hemodialysis: do patients with a failed renal transplant start in worse condition?
abstract: OBJECTIVE
  Predialysis management of patients with kidney transplant failure is a topic of growing interest. Herein we have reviewed a group of patients with a failed kidney transplant who returned to dialysis to compare them with patients with native kidney failure.
  
  
  METHODS
  We analyzed 25 patients who returned to dialysis after a failed renal transplant (group A) and 38 patients initiating dialysis after native kidney failure (group B).
  
  
  RESULTS
  We did not observe significant differences in the glomerular filtration rate (GFR), potassium, calcium, phosphorus, albumin, and hemoglobin levels between the 2 groups at the beginning of dialysis. Erythropoietin resistance index (ERI) was higher in group A. Progression of renal disease in the 2 years before dialysis was faster in group A, with a greater monthly decline in GFR and higher levels of systolic blood pressure. Renal transplant patients needed more evaluations in the 6 months before initiating dialysis: 1.75 +/- 0.97 vs 0.70 +/- 2.61 evaluations/month (P = .000). Also, the number of hospitalizations during the years before and after dialysis initiation was higher among group A. Patient survival after return to dialysis at 1 year was 75% in group A and 97% in group B (log-rank; P = .09).
  
  
  CONCLUSIONS
  Patients with a failed kidney allograft initiated dialysis in similar condition to those with native kidney failure. The faster GFR decline may be related to immunosuppressive treatment. Transplant patients needed more frequent evaluations and more hospitalizations before and after dialysis initiation, indicating a higher morbidity rate.
authors.affiliation: Nephrology Department, Hospital Universitario Dr Peset, Valencia, Spain. sanbelca@gmail.com
authors.forename: S
authors.initials: S
authors.lastname: Beltrán
authors.forename: E
authors.initials: E
authors.lastname: Gavela
authors.forename: J
authors.initials: J
authors.lastname: Kanter
authors.forename: A
authors.initials: A
authors.lastname: Sancho
authors.forename: A
authors.initials: A
authors.lastname: Avila
authors.forename: J L
authors.initials: JL
authors.lastname: Górriz
authors.forename: J F
authors.initials: JF
authors.lastname: Crespo
authors.forename: L M
authors.initials: LM
authors.lastname: Pallardó
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001774:Blood Chemical Analysis; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D004351:Drug Resistance; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D006435:Renal Dialysis / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D004921:Erythropoietin; D002784:Cholesterol